Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

p53 nuclear accumulation as an early indicator of lethal prostate cancer.

Quinn DI, Stricker PD, Kench JG, Grogan J, Haynes AM, Henshall SM, Grygiel JJ, Delprado W, Turner JJ, Horvath LG, Mahon KL.

Br J Cancer. 2019 Oct;121(7):578-583. doi: 10.1038/s41416-019-0549-8. Epub 2019 Aug 14.

PMID:
31409910
2.

Snowflakes in the heart: an ultrasonic marker of severe hypercoagulability.

Wang LW, Grygiel JJ, O'Neill JH, Fatkin D, Feneley MP.

Lancet. 2015 Jan 17;385(9964):302. doi: 10.1016/S0140-6736(14)62221-2. No abstract available.

PMID:
25706710
3.

Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer.

Horvath LG, Lelliott JE, Kench JG, Lee CS, Williams ED, Saunders DN, Grygiel JJ, Sutherland RL, Henshall SM.

Prostate. 2007 Jul 1;67(10):1081-90.

PMID:
17476687
4.

Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy.

Henshall SM, Horvath LG, Quinn DI, Eggleton SA, Grygiel JJ, Stricker PD, Biankin AV, Kench JG, Sutherland RL.

J Natl Cancer Inst. 2006 Oct 4;98(19):1420-4.

PMID:
17018789
5.

Aberrant neuropeptide Y and macrophage inhibitory cytokine-1 expression are early events in prostate cancer development and are associated with poor prognosis.

Rasiah KK, Kench JG, Gardiner-Garden M, Biankin AV, Golovsky D, Brenner PC, Kooner R, O'neill GF, Turner JJ, Delprado W, Lee CS, Brown DA, Breit SN, Grygiel JJ, Horvath LG, Stricker PD, Sutherland RL, Henshall SM.

Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):711-6.

6.

The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome.

Bauskin AR, Brown DA, Junankar S, Rasiah KK, Eggleton S, Hunter M, Liu T, Smith D, Kuffner T, Pankhurst GJ, Johnen H, Russell PJ, Barret W, Stricker PD, Grygiel JJ, Kench JG, Henshall SM, Sutherland RL, Breit SN.

Cancer Res. 2005 Mar 15;65(6):2330-6.

7.

Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer.

Horvath LG, Henshall SM, Lee CS, Kench JG, Golovsky D, Brenner PC, O'Neill GF, Kooner R, Stricker PD, Grygiel JJ, Sutherland RL.

Int J Cancer. 2005 Jan 20;113(3):415-22.

8.

Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer.

Afar DE, Bhaskar V, Ibsen E, Breinberg D, Henshall SM, Kench JG, Drobnjak M, Powers R, Wong M, Evangelista F, O'Hara C, Powers D, DuBridge RB, Caras I, Winter R, Anderson T, Solvason N, Stricker PD, Cordon-Cardo C, Scher HI, Grygiel JJ, Sutherland RL, Murray R, Ramakrishnan V, Law DA.

Mol Cancer Ther. 2004 Aug;3(8):921-32.

9.

Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression.

Horvath LG, Henshall SM, Kench JG, Turner JJ, Golovsky D, Brenner PC, O'Neill GF, Kooner R, Stricker PD, Grygiel JJ, Sutherland RL.

Prostate. 2004 May 15;59(3):234-42.

PMID:
15042598
10.

Membranous expression of secreted frizzled-related protein 4 predicts for good prognosis in localized prostate cancer and inhibits PC3 cellular proliferation in vitro.

Horvath LG, Henshall SM, Kench JG, Saunders DN, Lee CS, Golovsky D, Brenner PC, O'Neill GF, Kooner R, Stricker PD, Grygiel JJ, Sutherland RL.

Clin Cancer Res. 2004 Jan 15;10(2):615-25.

11.

Is year of radical prostatectomy a predictor of outcome in prostate cancer?

Cagiannos I, Karakiewicz P, Graefen M, Eastham JA, Ohori M, Rabbani F, Reuter V, Wheeler T, Kupelian P, Klein E, Huland H, Hammerer PG, Erbersdobler A, Schroeder F, Wildhagen M, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, Morash CG, Scardino PT, Kattan MW.

J Urol. 2004 Feb;171(2 Pt 1):692-6.

PMID:
14713788
12.

Prognostic significance of Gleason pattern in patients with Gleason score 7 prostate carcinoma.

Rasiah KK, Stricker PD, Haynes AM, Delprado W, Turner JJ, Golovsky D, Brenner PC, Kooner R, O'Neill GF, Grygiel JJ, Sutherland RL, Henshall SM.

Cancer. 2003 Dec 15;98(12):2560-5.

13.

A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer.

Cagiannos I, Karakiewicz P, Eastham JA, Ohori M, Rabbani F, Gerigk C, Reuter V, Graefen M, Hammerer PG, Erbersdobler A, Huland H, Kupelian P, Klein E, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, Morash CG, Scardino PT, Kattan MW.

J Urol. 2003 Nov;170(5):1798-803.

PMID:
14532779
14.

Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer.

Henshall SM, Afar DE, Rasiah KK, Horvath LG, Gish K, Caras I, Ramakrishnan V, Wong M, Jeffry U, Kench JG, Quinn DI, Turner JJ, Delprado W, Lee CS, Golovsky D, Brenner PC, O'Neill GF, Kooner R, Stricker PD, Grygiel JJ, Mack DH, Sutherland RL.

Oncogene. 2003 Sep 4;22(38):6005-12.

PMID:
12955079
15.

Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse.

Henshall SM, Afar DE, Hiller J, Horvath LG, Quinn DI, Rasiah KK, Gish K, Willhite D, Kench JG, Gardiner-Garden M, Stricker PD, Scher HI, Grygiel JJ, Agus DB, Mack DH, Sutherland RL.

Cancer Res. 2003 Jul 15;63(14):4196-203.

16.

Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion.

Quinn DI, Henshall SM, Brenner PC, Kooner R, Golovsky D, O'Neill GF, Turner JJ, Delprado W, Grygiel JJ, Sutherland RL, Stricker PD.

Cancer. 2003 Apr 15;97(8):1884-93.

17.

International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy.

Graefen M, Karakiewicz PI, Cagiannos I, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, Klein E, Kupelian P, Skinner DG, Lieskovsky G, Bochner B, Huland H, Hammerer PG, Haese A, Erbersdobler A, Eastham JA, de Kernion J, Cangiano T, Schröder FH, Wildhagen MF, van der Kwast TH, Scardino PT, Kattan MW.

J Clin Oncol. 2002 Aug 1;20(15):3206-12.

PMID:
12149292
18.

Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer.

Graefen M, Karakiewicz PI, Cagiannos I, Klein E, Kupelian PA, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, de Kernion J, Cangiano T, Schröder FH, Wildhagen MF, Scardino PT, Kattan MW.

J Clin Oncol. 2002 Feb 15;20(4):951-6.

PMID:
11844816
19.

Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models.

Quinn DI, Henshall SM, Haynes AM, Brenner PC, Kooner R, Golovsky D, Mathews J, O'Neill GF, Turner JJ, Delprado W, Finlayson JF, Sutherland RL, Grygiel JJ, Stricker PD.

J Clin Oncol. 2001 Aug 15;19(16):3692-705.

PMID:
11504751
20.

Frequent loss of estrogen receptor-beta expression in prostate cancer.

Horvath LG, Henshall SM, Lee CS, Head DR, Quinn DI, Makela S, Delprado W, Golovsky D, Brenner PC, O'Neill G, Kooner R, Stricker PD, Grygiel JJ, Gustafsson JA, Sutherland RL.

Cancer Res. 2001 Jul 15;61(14):5331-5.

21.

Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients.

Henshall SM, Quinn DI, Lee CS, Head DR, Golovsky D, Brenner PC, Delprado W, Stricker PD, Grygiel JJ, Sutherland RL.

Clin Cancer Res. 2001 Mar;7(3):544-50.

22.

Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer.

Henshall SM, Quinn DI, Lee CS, Head DR, Golovsky D, Brenner PC, Delprado W, Stricker PD, Grygiel JJ, Sutherland RL.

Cancer Res. 2001 Jan 15;61(2):423-7.

23.

Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy.

Quinn DI, Henshall SM, Head DR, Golovsky D, Wilson JD, Brenner PC, Turner JJ, Delprado W, Finlayson JF, Stricker PD, Grygiel JJ, Sutherland RL.

Cancer Res. 2000 Mar 15;60(6):1585-94.

24.

Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early-stage prostate cancer.

Ricciardelli C, Quinn DI, Raymond WA, McCaul K, Sutherland PD, Stricker PD, Grygiel JJ, Sutherland RL, Marshall VR, Tilley WD, Horsfall DJ.

Cancer Res. 1999 May 15;59(10):2324-8.

25.

Interaction of 5-fluorouracil with folates.

Mainwaring P, Grygiel JJ.

Aust N Z J Med. 1995 Feb;25(1):60. No abstract available.

PMID:
7786254
26.

Multiple atypical nevi: a cutaneous marker of germ cell tumors.

Raghavan D, Zalcberg JR, Grygiel JJ, Teriana N, Cox KM, McCarthy W, Flynn M.

J Clin Oncol. 1994 Nov;12(11):2284-7.

PMID:
7964941
27.

Oral cyclophosphamide for the management of hormone-refractory prostate cancer.

Raghavan D, Cox K, Pearson BS, Coorey GJ, Rogers J, Watt WH, Coates AS, McNeil E, Grygiel JJ.

Br J Urol. 1993 Nov;72(5 Pt 1):625-8.

PMID:
10071550
28.

Severe vascular adverse effects with thrombocytopenia and renal failure following emetogenic chemotherapy and ondansetron.

Coates AS, Childs A, Cox K, Forsyth C, Joshua DE, McNeil E, Grygiel JJ.

Ann Oncol. 1992 Nov;3(9):719-22.

PMID:
1450061
29.

A role for dextran in pseudomyxoma peritonei?

Ng LF, Grygiel JJ, Tattersall MH, Burns JC.

Med J Aust. 1992 Jun 15;156(12):886. No abstract available.

PMID:
1376399
30.

Phase II clinical trial of recombinant alpha-2 interferon for biopsy-proven metastatic or recurrent renal carcinoma.

Rosenthal MA, Cox K, Raghavan D, Grygiel JJ, Wines RD, Mameghan H, Rogers J.

Br J Urol. 1992 May;69(5):491-4.

PMID:
1623377
31.

Variability of methotrexate pharmacokinetics and pharmacodynamics.

Dawson AH, Grygiel JJ.

Agents Actions Suppl. 1988;24:226-35.

PMID:
3263759
32.

Pharmacokinetics of tiazofurin in the plasma and cerebrospinal fluid of rhesus monkeys.

Grygiel JJ, Balis FM, Collins JM, Lester CM, Poplack DG.

Cancer Res. 1985 May;45(5):2037-9.

33.

Identification of 6-mercaptopurine riboside in patients receiving 6-mercaptopurine as a prolonged intravenous infusion.

Zimm S, Grygiel JJ, Strong JM, Monks TJ, Poplack DG.

Biochem Pharmacol. 1984 Dec 15;33(24):4089-92. No abstract available.

PMID:
6594999
34.

Differential effects of cimetidine on theophylline metabolic pathways.

Grygiel JJ, Miners JO, Drew R, Birkett DJ.

Eur J Clin Pharmacol. 1984;26(3):335-40.

PMID:
6734695
35.

A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylatoplatinum (NSC 241240).

Curt GA, Grygiel JJ, Corden BJ, Ozols RF, Weiss RB, Tell DT, Myers CE, Collins JM.

Cancer Res. 1983 Sep;43(9):4470-3.

36.

Relationships between plasma theophylline clearance, liver volume and body weight in children and adults.

Grygiel JJ, Ward H, Ogborne M, Goldin A, Birkett DJ.

Eur J Clin Pharmacol. 1983;24(4):529-32.

PMID:
6861869
37.

Bioavailability and diurnal variation in absorption of sustained release theophylline in asthmatic children.

Coulthard KP, Birkett DJ, Lines DR, Grgurinovich N, Grygiel JJ.

Eur J Clin Pharmacol. 1983;25(5):667-72.

PMID:
6686557
38.

Metabolic activation as a basis for organ-selective toxicity.

Boyd MR, Grygiel JJ, Minchin RF.

Clin Exp Pharmacol Physiol. 1983 Jan-Feb;10(1):87-99. Review.

PMID:
6340874
39.

Effects of once daily indapamide and pindolol on blood pressure, plasma aldosterone concentration and plasma renin activity in a general practice setting.

Chalmers JP, Wing LM, Grygiel JJ, West MJ, Graham JR, Bune AJ.

Eur J Clin Pharmacol. 1982;22(3):191-6.

PMID:
7049706
40.

Cigarette smoking and theophylline clearance and metabolism.

Grygiel JJ, Birkett DJ.

Clin Pharmacol Ther. 1981 Oct;30(4):491-6.

PMID:
7285483
41.

Cimetidine: a specific inhibitor of hepatic aryl hydrocarbon hydroxylase (AHH) in the rat.

Drew R, Rowell J, Grygiel JJ.

Res Commun Chem Pathol Pharmacol. 1981 Jul;33(1):81-93.

PMID:
7268211
42.

Effect of age on patterns of theophylline metabolism.

Grygiel JJ, Birkett DJ.

Clin Pharmacol Ther. 1980 Oct;28(4):456-62.

PMID:
7408405
43.

The effect of metoclopramide and atropine on the absorption of orally administered mexiletine.

Wing LM, Meffin PJ, Grygiel JJ, Smith KJ, Birkett DJ.

Br J Clin Pharmacol. 1980 May;9(5):505-9.

44.

Comparison of labetalol, hydrallazine, and propranolol in the therapy of moderate hypertension.

West MJ, Wing LM, Mulligan J, Walkley J, Grygiel JJ, Graham JR, Chalmers JP.

Med J Aust. 1980 Mar 8;1(5):224-5.

PMID:
6990215
45.

Effects of allopurinol on theophylline metabolism and clearance.

Grygiel JJ, Wing LM, Farkas J, Birkett DJ.

Clin Pharmacol Ther. 1979 Nov;26(5):660-7.

PMID:
498708

Supplemental Content

Loading ...
Support Center